Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. by Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, Flasshove, M, Hense, J, Bojko, P, Metz, K, Moritz, T, Seeber, S, Nowrousian, MR

“…Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethasone (VED). …”

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. by Schütt, P, Buttkereit, U, Brandhorst, D, Lindemann, M, Schmiedl, S, Grosse-Wilde, H, Seeber, S, Nowrousian, MR, Opalka, B, Moritz, T

“…In patients treated with thalidomide, however, it remains to be seen whether the reduced expression of co-stimulatory molecules has functional relevance.…”

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. by Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Poser, M, Müller, S, Flasshove, M, Moritz, T, Seeber, S, Nowrousian, MR

“…Twenty-two patients received thalidomide in combination with dexamethasone and seven patients thalidomide alone. …”

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. by Schütt, P, Brandhorst, D, Stellberg, W, Poser, M, Ebeling, P, Müller, S, Buttkereit, U, Opalka, B, Lindemann, M, Grosse-Wilde, H, Seeber, S, Moritz, T, Nowrousian, MR

“…Conventional-dose chemotherapy resulted in significantly reduced CD4+ and even further decline of CD4+/CD45RO+ and CD19+ cells, most notably in relapsed patients. Additional thalidomide treatment had no significant effects on these parameters. …”